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Trough level Adapted infliXImab Treatment trial; TNF-alpha - tumor necrosis factor-alpha  
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ABSTRACT 
Biologics have transformed management of inflammatory diseases. To optimize outcomes 
and reduce costs, dose adjustment informed by circulating drug levels has been proposed. We 
aimed to determine the real-world clinical utility of therapeutic drug monitoring in psoriasis. 
Within a multicenter (n=60) prospective observational cohort, 544 psoriasis patients were 
included who were on adalimumab monotherapy, with at least one serum sample and PASI 
(Psoriasis Area and Severity Index) score available within the first year. We present models 
giving individualized probabilities of response for any given drug level: a minimally effective 
drug level of 3.2 µg/ml discriminates responders (PASI75: 75% improvement in baseline 
PASI) from non-responders and gives an estimated PASI75 probability of 65% (95% CI 60-
71%). At 7ug/ml, PASI75 probability is 81% (95% CI 76-86%); beyond 7ug/ml, the drug 
level/response curve plateaus. Crucially, drug levels are predictive of response 6 months 
later, whether sampled early or at steady state. We confirm serum drug level to be the most 
important factor determining treatment response, highlighting the need to take drug levels 
into account when searching for biomarkers of response. 
This real-world study with pragmatic drug level sampling provides evidence to support the 
proactive measurement of adalimumab levels in psoriasis to direct treatment strategy, and is 
relevant to other inflammatory diseases.  
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INTRODUCTION 
Biologic therapies have transformed the treatment paradigm in immune-mediated 
inflammatory diseases (IMID). Complete disease remission is now achievable in people with 
psoriasis, rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), where inhibition 
of the inflammatory cytokine tumour necrosis factor alpha (TNF-alpha) remains the first-line 
biologic strategy. However, there are wide variations in response, with a significant number 
of patients not responding (primary treatment failure) or losing response over time (secondary 
treatment failure) (Garces et al., 2013, Yanai and Hanauer, 2011).  Some of this heterogeneity 
may be explained by differences in the amount of drug available at the target tissue, which in 
turn is influenced by adherence and pharmacokinetic covariates such as weight and drug 
immunogenicity (formation of anti-drug antibodies [ADA]). Therapeutic drug monitoring 
using measurement of serum drug levels (a proxy for tissue levels) and/or ADA thus holds 
potential to optimize management, and a strong correlation between TNF inhibitor serum 
trough levels, ADA and treatment response has been described in IBD, RA and psoriasis  
(Baert et al., 2003, Chen et al., 2015, Lecluse et al., 2010). Indeed, a recent study using 
adalimumab clinical trial data in 1212 psoriasis patients reported that responders at 16 weeks 
had higher adalimumab concentrations than non-responders (6.3 vs. 2.2 µg/mL). Bodyweight 
was a significant covariate in the pharmacokinetic model, and the presence of ADA resulted 
in lower adalimumab exposure and efficacy (Mostafa et al., 2017). 
Effective therapeutic drug monitoring requires the definition of a therapeutic range, and 
although parameters for serum adalimumab levels have been proposed in the context of 
several IMID (Menting et al., 2015, Pouw et al., 2015, Roblin et al., 2014, Yarur et al., 2016), 
these have not yet been validated in psoriasis patients. Further, the utility of drug level as a 
predictor of subsequent response has not been investigated in psoriasis other than in a 
previous preliminary study by our group (Mahil et al., 2013). Defining clinical outcomes in 
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IBD and RA is inherently challenging – often relying on composite indices comprising 
patient-reported criteria and non-specific biochemical markers. Psoriasis provides a disease 
model less encumbered by such issues, since treatment response can be visually observed and 
easily quantified. Furthermore, biologics are generally used as monotherapy (whereas 
patients with IBD and RA are often co-prescribed immunosuppressants such as methotrexate, 
known to reduce the formation of ADA). Here, we capitalize on a real-world bioresource 
from a large multicenter cohort study BSTOP (Biomarkers of Systemic Treatment Outcomes 
in Psoriasis) within the UK pharmacovigilance registry BADBIR (British Association of 
Dermatologists Biologic Interventions Registry) to investigate the clinical utility of 
therapeutic drug monitoring as applied to the exemplar TNF inhibitor adalimumab. This work 
is particularly timely with the imminent release of adalimumab biosimilars to market, as 
optimizing outcomes may deliver comparable efficacy to newer biologics, but at significantly 
lower cost. We explore the relationship between drug levels and treatment response, 
accounting for individual patient characteristics to determine (i) the adalimumab therapeutic 
range ie. both the minimal effective drug level and the drug level beyond which response 
plateaus (ii) whether drug level predicts longer-term response.  Given the nature of this real-
world dataset, findings are generalizable to clinical practice. 
 
RESULTS 
Description of the cohort and patient characteristics   
At the time of the data cut in April 2017, 2019 patients were currently or previously on 
adalimumab monotherapy within the BSTOP cohort. 1242 of these consented to give 
longitudinal serum samples; within this, serum samples were actually collected from 833 
patients. Baseline characteristics were similar between those providing and not providing 
samples (Table 1, eTable 7). Of the 833 patients providing serum samples, 544 patients also 
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had PASI data within 12 months of starting adalimumab (Figure 1). These 544 patients were 
included in the analysis (Table 1), and of these, 375 (69%) were biologic-naïve. 
The demographics and clinical characteristics of the cohort were consistent with severe 
disease (predominantly male, with an elevated BMI and mean baseline PASI 13.5 (sd: 6.7) 
(Table 1).  Drug levels were sampled according to standard clinical care (median time from 
last dose 7 days, IQR 6 to10 days, range 0 to 14 days, data available on n=349 samples), 
giving a mean drug level of 5.83 µg/ml (sd: 3.86, range 0.01 to 22 µg/ml).  
 
 
Figure 1: Flow diagram of patients and samples 
Flow diagram showing the rules applied to derive the three datasets. 
As Figures 1 and 2 show, three datasets were derived: a therapeutic range dataset to 
investigate the relationship between drug levels and same-day response; an early dataset to 
investigate the relationship between drug levels taken before 12 weeks and 6-month response; 
and a steady state dataset to investigate the relationship between drug levels taken any time 
after 9 weeks and response 6 months later.  
 
Figure 2: Timeline of drug levels and response in each dataset  
Timeline showing when drug level and response was measured in each of the three datasets. In the 
therapeutic range dataset, response was measured on the same day as drug level. The other two 
datasets were derived to investigate use of drug levels to predict response 6 months later: in the 
early dataset, response was measured at 6 months after start of treatment; in the steady state 
dataset, response was measured 6 months after drug level. Statistical analyses conducted using each 
dataset are also shown.  
 
Defining the therapeutic range 
(i) Drug level discriminates responders from non-responders  
Using the therapeutic range dataset (drug levels with PASI recorded on the same day), 
empirical ROC curves (Menting et al., 2015) were generated for all three outcomes. For 
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PASI75, drug level discriminated responders from non-responders with an AUC of 0.74 
(95% CI 0.68 to 0.79) (Figure 3a, Table 2). A lower limit of 3.2 µg/ml identified patients 
achieving PASI75 with our pre-set minimum sensitivity of 80% (red dot on Figure 3a; 
specificity 58%; overall classification accuracy 73%). This drug level showed comparable 
sensitivity for the secondary outcomes PASI90 (82%) and PASI≤1.5 (85%), but specificity 
and overall classification accuracy were lower (eTable 1). 
 
 
(ii) Likelihood of response increases with increasing drug level, and then plateaus    
Using the therapeutic range dataset (drug levels with PASI recorded on the same day), a 
descriptive concentration effect curve (Menting et al., 2015) was next generated to confirm 
that clinical response increases with increasing drug level, then plateaus for groups with 
median drug level ≥4.6 µg/ml (red dot on Figure 3b), corresponding to a percentage PASI 
change of 90.7% (IQR 83.7 to 99.4%, range 16.2% to 100%). However, the interquartile 
ranges on this curve show variability in response, likely caused by other clinical and 
confounding factors including ADA, time from last dose, sex, age and disease duration. 
 
Figure 3: (a) Empirical ROC curve (b) Concentration effect curve  
(a) Empirical ROC curve for PASI75 response. Cutpoint (red dot) chosen to provide a minimum 
sensitivity of 80%. (b) Concentration effect curve of median percentage change in PASI against 
median drug level. These summaries are calculated for approximately equally sized groups of 
observations (between 23 and 52) having similar drug levels. Vertical bars: interquartile range (IQR); 
grey horizontal lines: indicators of PASI75 and PASI90 response; red dot: drug level beyond which 
clinical response plateaus. 
 
(iii) Selecting an upper limit of the therapeutic range taking other covariates into 
account 
To take clinical and confounding covariates into account, multivariable mixed effects logistic 
regression modelling was carried out using the therapeutic range dataset. The results were 
consistent with the empirical analysis: for the primary outcome of PASI75, the best-fitting 
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model included (transformed) drug level and ethnicity as covariates (Table 3, eTable 2) and 
the probability of PASI75 response plateaued with increasing drug level, supporting the 
concept of an upper-bounded therapeutic range (Figure 4). We selected 7 µg/ml as the upper 
limit of the therapeutic range since this achieves our minimum stipulated 80% probability of 
response (81%, 95% CI 76% to 86%) (Figure 4), whereas the drug level at which the 
concentration effect curve appeared to plateau (4.6 µg/ml) has a lower probability of response 
(73%, 95% CI 68% to 77%).  
For the PASI90 and PASI≤1.5 outcomes, drug level remained the most important determinant 
of response. Additional covariates appear significant for PASI90 (baseline PASI, treatment 
duration and biologic naive status) and PASI≤1.5 (gender and biologic naive status). 
However, this should be treated with caution given the small number of patients achieving 
PASI90 and PASI≤1.5 (eTable 2, eTable 5, eFigure 1).  
 
Figure 4: 
Probability of PASI75 based on same-day drug level (therapeutic range dataset)  
Probability of response is split by ethnicity (red is white ethnicity; dark blue is all other ethnicities). 
The grey vertical line is at a drug level of 7 µg/ml, where there is at least 80% probability of response 
on average for all patients. This line crosses the red curve for patients of white ethnicity at a 
probability of response >80%, but the probability is lower for the non-white group (dark blue 
line).The green dots indicate the proportion of patients per group achieving PASI75.  Note that the 
groups are calculated in the same way as for the concentration effect curve in Figure 2b, and that 
they are not split by other covariates. The probabilities are marginal predicted means due to the 
inclusion of a random effect in the model. 
Similar curves are seen for probability of PASI75 in the other datasets (early and steady state). 
 
Using drug level to predict subsequent response  
i) Early drug levels predict response at 6 months 
To determine whether drug levels indicate response status at later time points, multivariable 
logistic regression modelling was carried out using the early dataset (drug levels taken 
between 1-12 weeks with PASI recorded at 6 months). For the primary outcome of PASI75, 
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independent predictors were (transformed) drug level and ethnicity (Table 3, eTable 3). These 
same covariates were included in the final PASI90 model, and drug level and baseline PASI 
were included in the PASI≤1.5 model (eTable 5). Similar to the analysis using the therapeutic 
range dataset (exploring the relationship between drug levels and response on the same day), 
the probability of response at 6 months increases with increasing early drug level (PASI75 
Table 3, eFigure 2a; PASI90 and PASI≤1.5 eTable 5, eFigures 2b and 2c). The upper limit of 
7 µg/ml (defined in the therapeutic range dataset, Figure 4) corresponds to a 78% (95% CI 
71% to 85%) probability of 6-month response using early drug levels (Table 2, eFigure 2a). 
We also performed a sensitivity analysis by fitting the model to very early samples (4 weeks 
+/- 1 week after treatment initiation) given our pilot data showing that higher adalimumab 
levels in responders versus non-responders were detectable at 4 weeks 11, and acknowledging 
the overlap between our early dataset and steady state dataset. We found a similar 
relationship between drug levels and PASI75 response (eTable 6). 
ii) Steady state drug levels predict response 6 months later 
Finally, we explored whether steady state drug levels in patients established on therapy could 
predict treatment outcomes 6 months later. Multivariable mixed effects logistic regression 
modelling was carried out using the steady state dataset (drug levels taken >9 weeks after 
treatment start with PASI recorded 6 months later) (Table 3, eTable 4). Again, for the 
primary outcome of PASI75, (transformed) drug level was the single most important 
predictor of response (OR[(sqrt) drug level] 2.78, 95%CI 1.83 to 4.24, P<.001) (Table 3), 
with increasing probability of response with increasing drug level (Figure 4c). This 
relationship between drug level and response was also seen using the PASI90 and PASI≤1.5 
outcomes (eFigures 3a and 3b, eTable 5); the covariates palm psoriasis and biologic naive 
status were also significant for these outcomes respectively. 
Clinical utility of the therapeutic range 
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Table 2 gives the standard estimates of clinical utility for our therapeutic range for PASI75 
(3.2 to 7 µg/ml). Notably, this has comparable diagnostic accuracy whether used to determine 
response on the same day as the drug level, or response 6 months later. Bearing our 
therapeutic range in mind, 72/125 (57.60%) of samples with a corresponding response less 
than PASI75 had a drug level below 3.2 µg/ml, and 69/171 (40.35%) of samples with a 
corresponding PASI90 response had a drug level greater than or equal to 7 µg/ml. This 
suggests that a significant proportion of the cohort would benefit from treatment 
modification.  
 
DISCUSSION 
Key results  
In the largest real-world multicenter cohort across any IMID to date, we have determined the 
therapeutic range for adalimumab in moderate to severe psoriasis and calculate probabilities 
of response for any given drug level, for multiple outcomes (PASI75, PASI90 and absolute 
PASI≤1.5). We also show that drug levels can be used to predict response at later time points, 
whether taken early in the treatment course or at steady state. A minimal effective circulating 
drug level of 3.2 µg/ml distinguishes PASI75 responders from non-responders, and a target 
drug level of 7 µg/ml provides an 80% probability of achieving a PASI75 response. As 
expected, there is a lower probability (51%) of achieving higher disease clearance (PASI90) 
at the same target drug level. Notably, measurement of ADA provides no additional clinical 
utility - presumably due to the correlation between drug levels and ADA. These key findings 
support the practical utility of measuring drug levels at routine clinical visits (irrespective of 
timing in relation to drug administration, and despite not being trough levels), and provide 
drug level thresholds at which to consider changes in adalimumab treatment.    
Clinical implications  
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Our findings are consistent with the only other study conducted in psoriasis, which was dual-
center and reported a therapeutic range of 3.51 to 7.00 µg/ml (Menting et al., 2015), but did 
not take into account clinical or other covariates such as ADA, nor comment on clinical 
utility. This work builds on our previous pilot data, showing that adalimumab levels at 4 
weeks were significantly higher in responders than non-responders (Mahil et al., 2013). Very 
few studies across any IMID have paid attention to early drug levels, and to our knowledge, 
only one small study in IBD (Baert et al., 2014) has looked at early adalimumab levels as a 
predictor of subsequent treatment response. This may open up a powerful clinical opportunity 
to optimize therapy before drug levels have reached steady state, well ahead of clinical 
relapse. However, it is significant that drug level at steady state (≥9 weeks) is also associated 
with response 6 months later, suggesting that there is potential to optimize therapy even once 
patients are established on treatment. Our results may be generalizable across other IMID, 
given comparable therapeutic ranges for adalimumab reported in RA (5-8 µg/ml) (Pouw et 
al., 2015) and IBD (5.0 to 5.9 µg/mL or 4.9 to 7.5 µg/mL (Roblin et al., 2014, Yarur et al., 
2016)); and comparable mean levels in ankylosing spondylitis (Kobayashi et al., 2012). 
A minimal effective drug level indicates the threshold below which treatment should be 
modified (dose escalation or treatment switch). Such an approach has been tested in IBD, 
with the TAXIT trial demonstrating similar remission rates in IBD patients on adjusted 
infliximab dosing based on drug-level, but with fewer flares than the conventional approach  
(Vande Casteele et al., 2015).  An upper limit of the therapeutic range identifies a patient 
population that might benefit from dose minimization. This has been simulated in an RA 
cohort and whilst cost-effective, led to a reduction in quality-adjusted life years for at least a 
quarter of patients (Krieckaert et al., 2015). By comparison, our modelling approach may 
have an advantage in allowing for individualized prediction of response. Indeed, our data 
indicate that both the stringency of the outcome (for example PASI75 or PASI90), and the 
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threshold set for the probability of response, need to be considered when defining the upper 
limit of the therapeutic range (and therefore the drug level chosen to implement dose 
minimization). This will help optimize cost-effectiveness and minimize the proportion of 
patients subjected to inappropriate dose reduction.   
From a biological perspective, the finding that clinical response rate plateaus beyond a certain 
drug level likely reflects the point at which most of the TNF in psoriatic skin is neutralized by 
adalimumab. In turn, this may indicate that in patients for whom clinical response plateaus at 
a lower drug level, alternative non-TNF pathways possibly play a greater role in driving their 
psoriasis.  
The finding that biologic naïve status and ethnicity may predict longer-term response requires 
further validation, as these covariates were not consistent across outcomes. Our data suggest 
that although biologic naïve status does not appear to be important for achieving PASI75, it 
does appear to be influential for achieving clearance (PASI90 or PASI<1.5). This is 
consistent with existing evidence that biologic naïve status may influence outcome 
(nice.org.uk/guidance/cg153).  
Our findings related to ethnicity should be treated with particular caution, because very few 
patients within the study cohort were of non-white ethnicity. Intriguingly, across the 
BADBIR cohort as a whole, we found non-white ethnicity to be associated with a reduced 
likelihood of response to biologics up to one year (Warren R.B. et al., in press).  
Finally, we have confirmed serum drug level to be the single most important factor 
determining treatment response - whether sampled a few weeks after treatment initiation, or 
at steady state. This underpins the importance of taking drug levels into account when 
searching for biomarkers and mechanisms of treatment response such as genetic factors.  
Indeed, the need to incorporate a richer set of clinical information, such as seropositivity and 
disease duration, was recently highlighted in an innovative crowdsourced assessment of the 
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common genetic contribution to predicting TNF-antagonist treatment response in RA 
(Sieberts et al., 2016).  
Strengths and limitations  
A key strength of this study is high external validity, since more than 50% of all UK psoriasis 
patients on biologics are registered on BADBIR, and 95% of UK dermatology centers 
prescribing biologics for psoriasis contribute data to BADBIR. In order to maximize 
inclusivity, generalizability and sample size, we developed a prespecified research protocol 
with inclusion criteria designed to capture a truly representative patient sample. This 
approach, together with the real-world nature of the cohort necessitating pragmatic sampling, 
introduces heterogeneity into our dataset. This heterogeneity reflects our strategy to 
maximize inclusivity and minimize selection bias.  
In terms of potential limitations, the validity of the therapeutic range is limited to within one 
year of start of treatment, since this was the selected cohort duration. Most patients in the UK 
receive the licensed dose for adalimumab (40 mg fortnightly), so whilst dose escalation 
would be a logical clinical strategy for individuals with subtherapeutic drug levels, this 
requires confirmation in a clinical trial setting and would have pharmacoeconomic 
implications. On the other hand, the advent of adalimumab biosimilars at a fraction of the 
cost of the original drug means that dose optimization strategies remain highly relevant. 
Another potential limitation is use of pragmatic serum sampling at routine clinic visits; to 
account for the timing of samples we included time from last dose as a covariate, and 
although this was not significant at the univariate level, we only had this data available on 
around a third of samples. Nevertheless, we identified a comparable range to Menting et al 
(Menting et al., 2015) who reported on trough drug levels, suggesting that limiting sampling 
to trough levels may not be an absolute requirement. Finally, covariates are not always 
consistent across outcomes or datasets, due to statistical artefacts when using different 
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subsets of patients - thus our findings require replication. Indeed, the model fit as measured 
by pseudo R2 indicates that although drug level is important, this model could potentially be 
improved using covariates that have not been considered in this study.  
Conclusions 
We provide evidence to support the proactive measurement of drug levels in the management 
of psoriasis with adalimumab therapy. Drug levels taken both early and at steady state during 
the treatment course could be used to predict and therefore optimize clinical outcome.  These 
findings are of potential relevance to other IMID.  
 
MATERIALS & METHODS 
Ethics approval 
The study was conducted in the spirit of the 1996 International Conference on Harmonisation 
in Good Clinical Practice (ICH-GCP) 1996, and in accordance with the 2008 Declaration of 
Helsinki. The study protocol was approved by The South East London REC 2 Ethics 
Committee (11/H0802/7).  Written informed consent was obtained from all subjects prior to 
enrolment. 
Patients and Setting 
BSTOP is a prospective, multicenter (n=60) observational study to establish clinically 
relevant markers of outcomes to systemic therapies in people with severe psoriasis.  All 
adults in the UK fulfilling the BSTOP inclusion and exclusion criteria (BSTOP protocol at 
https://bit.do/BSTOPDOCS) and enrolled onto BADBIR (http://www.badbir.org/) were 
invited to participate.  BADBIR has recruited >12,000 psoriasis patients since 2007, and is 
unique worldwide in terms of size and depth of phenotyping. Inclusion criteria include: 
dermatologist’s diagnosis of psoriasis; age >16 years; and started on, or switched to a 
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conventional systemic therapy or a biological therapy within the previous 6 months. Detailed 
information is recorded, including demographics, comorbidities, treatments and adverse 
effects. Clinical response is assessed longitudinally using the gold standard assessment tool 
PASI. 
Pharmacokinetic Measurements 
Venous blood samples were collected between June 2009 and December 2016 during routine 
clinic reviews, without reference to treatment administration (ie. trough/non-trough not 
specified), immediately centrifuged at 2000 g for 10 minutes and serum aliquots frozen at -80 
°C. In this pragmatic study, samples were not collected from every patient at every time 
point. Samples within the first year of treatment (n=961, maximum 4 samples/patient) were 
selected and sent in batches to Sanquin for measurement of adalimumab concentration 
(enzyme-linked immunosorbent assay, ELISA, µg/ml (Menting et al., 2015)) and ADA 
(radioimmunoassay, RIA, ADA positive cutoff: >12 arbitrary units/ml (Menting et al., 
2015)).  
Outcome Measures 
Primary treatment response was defined as achieving a 75% reduction in PASI from baseline 
(PASI75); secondary outcomes were (i) 90% reduction in PASI from baseline (PASI90) and 
(ii) an absolute measure of response, PASI of ≤1.5 (results in Supplementary Material). 
Baseline PASI was defined as the most recent PASI recorded prior to the date of the first 
drug dose within the preceding 6 months (Iskandar et al., 2015, Warren et al., 2015).   
Statistical Methods 
Analyses for PASI75 and PASI90 responses were restricted to patients with baseline PASI 
>10 as an accepted criterion for severe disease (nice.org.uk/guidance/cg153) and to minimize 
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confounding due to pre-biologic treatments – of particular relevance in this real-world 
dataset. 
Identification of therapeutic range 
The therapeutic range dataset (Figure 1, Figure 2) included samples that were taken at steady 
state (≥9 weeks (Awni et al., 2003)), with PASI scores recorded on the same day. Empirical 
Receiver Operating Characteristic (ROC) curve analysis (Menting et al., 2015) was used to 
identify the lower limit of the therapeutic range – specifically, the drug level at which 
responders are detected with a minimum sensitivity of 80%.  
A descriptive concentration effect curve (Menting et al., 2015) was generated to confirm that 
clinical response plateaus beyond a certain drug level. Multivariable mixed effects logistic 
regression was then used to identify an upper drug level, and to explore the relationship 
between drug level and treatment response in the presence of other relevant covariates. A 
random intercept term was used to account for correlation between repeated samples on the 
same patient. Univariate mixed effects logistic regression models explored the relationship 
between treatment response and i) drug level ii) other confounding covariates including 
ADA, time from last dose, sex, age and disease duration. For continuous covariates, the best-
fitting simple non-linear transformation was chosen based on reduction in the Akaike 
Information Criterion (AIC). Covariates associated with response at significance level p<0.1 
were taken forward to the multivariable modelling stage. Forward selection techniques were 
then used, with covariate inclusion based on significance level p<0.05. Pseudo R2 
(McFadden's for fixed effect models, conditional and marginal for mixed models (Nakagawa 
and Schielzeth, 2013)) and AIC were calculated to assess model fit.  Finally, an upper limit of 
the therapeutic range was defined based on this multivariable model for PASI75, with the 
target probability of response set at 80%.  
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Using drug level to predict subsequent response  
To investigate whether drug level predicts subsequent outcome, two further datasets were 
derived: an early dataset comprising samples taken between 1 and 12 weeks with a 
corresponding PASI 6 months (122 to 243 days) after start of treatment and a steady state 
dataset comprising samples taken at steady state (≥9 weeks (Awni et al., 2003)) with a 
corresponding PASI 6 months (122 to 243 days) after the sample date. Multivariable mixed 
effects logistic regression models were considered to explore the relationship between drug 
level and other covariates with patient response 6 months later. For the early dataset a random 
effect was not included, due to the small number of patients with multiple samples. All 
analyses were carried out using Stata version 14 (StataCorp, 2015) on a complete case basis. 
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Table 1: Summary statistics for the full cohort, therapeutic range dataset, early dataset 
and steady state dataset 
 
 Full cohort  
 
(n=544 patients with 
961 samples) 
Therapeutic range 
dataset  
(n= 303 patients with 
409 samples) 
Early dataset  
 
(n=120 patients with 
159 samples) 
Steady state dataset  
 
(n=244 patients with 
322 samples) 
Covariate Mean 
(sd) 
Complete 
data n 
(%) 
Mean 
(sd) 
Complete 
data n 
(%) 
Mean 
(sd) 
Complete 
data n 
(%) 
Mean 
(sd) 
Complete 
data n 
(%) 
Baseline 
PASI  13.5  (6.7) 
495  
(91.0) 
15.9 
(5.6) 
303 
(100.0) 
16.2 
(6.4) 
120 
(100.0) 
15.9 
(5.6) 
244 
(100.0) 
Height (cm) 172.3 
(10.3) 
520  
(95.6) 
172.0 
(10.1) 
295  
(97.4) 
172.4 
(9.3) 
114  
(95.0) 
172.3 
(10.3) 
239  
(98.0) 
Weight (kg) 90.9 
(20.4) 
471  
(86.6) 
92.3 
(20.7) 
277  
(91.4) 
92.3 
(22.2) 
106  
(88.3) 
92.9 
(21.1) 
223  
(91.4) 
Waist (cm) 102.1 
(15.6) 
443  
(81.4) 
103.0 
(16.0) 
266  
(87.8) 
103.2 
(16.9) 
103  
(85.8) 
103.8 
(15.7) 
214  
(87.7) 
BMI (kg/m2) 30.8  
(6.7) 
465  
(85.5) 
31.3 
(7.2) 
274  
(90.4) 
31.2 
(7.3) 
106  
(88.3) 
31.3 
(7.0) 
221  
(90.6) 
Age (years) 44.3 
(12.2) 
544 
(100.0) 
44.0 
(12.3) 
303 
(100.0) 
43.8 
(12.4) 
120 
(100.0) 
44.1 
(12.2) 
244 
(100.0) 
Disease 
duration 
(years) 
22.0 
(12.0) 
498  
(91.5) 
21.5 
(12.4) 
282  
(93.1) 
20.8 
(11.5) 
104  
(86.7) 
21.1 
(11.8) 
233  
(95.5) 
 n (%) 
 
n (%) 
 
n (%) 
 
n (%) 
 
Ethnicity – 
white 484 (89.0%) 
544 
(100.0) 
272 
(89.8) 
303 
(100.0) 
103 
(85.8) 
120 
(100.0) 
216 
(88.5) 
244 
(100.0) 
Gender – 
male  338 (62.1) 
544 
(100.0) 
191 
(63.0) 
303 
(100.0) 
80 
(66.7) 
120 
(100.0) 
161 
(66.0) 
244 
(100.0) 
Inflammatory 
arthritis  109 (23.5) 
464  
(85.3) 
62  
(22.6) 
274  
(90.4) 
27 
(26.2) 
103  
(85.8) 
54  
(24.1) 
224  
(91.8) 
Ever 
smoked  298 (56.7) 
526  
(96.7) 
172 
(57.9) 
297  
(98.0) 
66 
(57.9) 
114  
(95.0) 
141 
(58.5) 
241  
(98.8) 
Palm 
psoriasis 
87  
(16.9) 
515  
(94.7) 
46  
(16.0) 
288  
(95.0) 
21 
(19.4) 
108  
(90.0) 
38  
(16.4) 
232  
(95.1) 
Biologic 
naive 
375 
(68.9) 
544 
(100.0) 
237 
(78.2) 
303 
(100.0) 
97 
(80.8) 
120 
(100.0) 
189 
(77.5) 
244 
(100.0) 
 
Summaries for the therapeutic range, early sample and steady state datasets are restricted to patients with baseline PASI > 
10. Height, waist and BMI measurements provided for information only; weight used in modelling. 
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Table 2: Diagnostic accuracy of the therapeutic range for PASI75 response 
 
 
 Drug levels and response 
(same-day) 
Drug levels as a predictor of subsequent response  
(6 months) 
  early steady state 
Cutpoint+ 
(µg/ml) 
3.2 7 3.2 7 3.2 7 
Sensitivity 80.28% 38.38% 86.61% 40.18% 77.46% 39.44% 
Specificity 57.60% 84.80% 44.68% 74.47% 55.96% 84.40% 
Overall 
classification 
accuracy 
73.35% 52.57% 74.21% 50.31% 70.19% 54.66% 
Positive 
Predictive Value 
81.14% 85.16% 78.86% 78.95% 77.46% 83.17% 
Negative 
Predictive Value 
56.25% 37.72% 58.33% 34.31% 55.96% 41.63% 
AUC 
(95% CI) 
0.74  
(0.68,0.79) 
0.70  
(0.59,0.80) 
0.72  
(0.66,0.78) 
Response rate: 
all samples 
69.44% 70.44% 66.15% 
Response rate: 
samples with 
drug level < 
cutpoint * 
43.75% 62.28% 41.67% 65.69% 44.04% 58.37% 
Response rate: 
samples with 
drug level ≥ 
cutpoint * 
81.14% 85.16% 78.86% 78.95% 77.46% 83.17% 
Probability of 
response ** 
(95% CI) 
65% 
(60,71%) 
81% 
(76,86%) 
61%  
(51,70%) 
78%  
(71,85%) 
77%  
(71,83%) 
64%  
(58,70%) 
 
Note: analyses are based on 409 samples from 303 patients for the therapeutic range, on 159 samples from 120 patients 
for the early samples and 322 samples on 244 patients for the steady state dataset. 
+
 A cutpoint of 3.2 indicates that samples with a drug level ≥3.2 are predicted to correspond with response. 
* Response rates for samples above and below cutpoints are equivalent to positive predictive value and (1 – negative 
predictive value) respectively. 
**  Derived from the final multivariable models given in Table 3.  
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Table 3: Final multivariable models for PASI75 response based on drug level and additional covariates (therapeutic range dataset) and 
predicting PASI75 response 6 months later (early dataset, steady state dataset)  
 
Therapeutic range (Mixed effects logistic regression model) 
 Covariate Coefficient 
(s.e) 
P value 95% CI OR (95% CI)  Marginal/ 
Conditional 
Pseudo R2 
Number of 
samples 
Number of 
responders (% 
of samples) 
PASI75 Sqrt(drug level) 1.10 (0.20) <.001 (0.69,1.50) 2.99 (2.00,4.46) 
0.25/0.38 
 
409 samples on 
303 patients 
 
284 (69.44) Ethnicity – 
white 
1.15 (0.46) .013 (0.24,2.06) 3.17 (1.28,7.85) 
Early samples (Logistic regression model) 
 Covariate Coefficient 
(s.e) 
P value 95% CI OR (95% CI) Pseudo R2 Number of 
samples 
Number of 
responders (% 
of samples) 
PASI75 Sqrt(drug level) 1.00 (0.26) <.001 (0.49,1.52) 2.73 (1.63,4.57) 0.10 
 
 
159 samples on 
120 patients 
112 (70.44) 
Ethnicity – 
white 
1.05 (0.51) .039 (0.06,2.04) 2.86 (1.06,7.72) 
Steady state (Mixed effects logistic regression model) 
 Covariate Coefficient 
(s.e) 
P value 95% CI OR (95% CI) Marginal/ 
Conditional 
Pseudo R2 
Number of 
samples 
Number of 
responders (% 
of samples) 
PASI75 Sqrt(drug level) 1.02 (0.21) <.001 (0.60,1.44) 2.78 (1.83,4.24) 0.16/0.50 322 samples on 
244 patients 
213 (66.15) 
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Figure Legends 
 
Figure 1: Flow diagram of patients and samples 
Flow diagram showing the rules applied to derive the three datasets. 
 
Figure 2: Timeline of drug levels and response in each dataset  
Timeline showing when drug level and response was measured in each of the three datasets. In the therapeutic range dataset, response was measured on 
the same day as drug level. The other two datasets were derived to investigate use of drug levels to predict response 6 months later: in the early dataset, 
response was measured at 6 months after start of treatment; in the steady state dataset, response was measured 6 months after drug level. Statistical 
analyses conducted using each dataset are also shown.  
 
 
Figure 3: (a) Empirical ROC curve (b) Concentration effect curve  
(a) Empirical ROC curve for PASI75 response. Cutpoint (red dot) chosen to provide a minimum sensitivity of 80%.  
(b) Concentration effect curve of median percentage change in PASI against median drug level. These summaries are calculated for approximately equally 
sized groups of observations (between 23 and 52) having similar drug levels. Vertical bars: interquartile range (IQR); grey horizontal lines: indicators of 
PASI75 and PASI90 response; red dot: drug level beyond which clinical response plateaus. 
 
Figure 4: 
Probability of PASI75 based on same-day drug level (therapeutic range dataset)  
Probability of response is split by ethnicity (red is white ethnicity; dark blue is all other ethnicities). The grey vertical line is at a drug level of 7 µg/ml, where 
there is at least 80% probability of response on average for all patients. This line crosses the red curve for patients of white ethnicity at a probability of 
response >80%, but the probability is lower for the non-white group (dark blue line).The green dots indicate the proportion of patients per group achieving 
PASI75.  Note that the groups are calculated in the same way as for the concentration effect curve in Figure 2b, and that they are not split by other 
covariates. The probabilities are marginal predicted means due to the inclusion of a random effect in the model. 
Similar curves are seen for probability of PASI75 in the other datasets (early and steady state). 
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